HALO logo
halo search icon
PHARM
Pharming Group NV

PHARM · Pharming Group NV

0.99

EUR
-0.029 (-2.874%)
24/08/2026 12:00:00 AM
+1
Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

Euro719.11M

PE

385.40

EV/EBITDA

36.1

DIV Yield

0%

Payout Ratio

0%

MQV Rating

4Weak

As at 24/08/2026 12:00:00 AM

Price Chart

Description

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

  • All-Companies
  • All-Consensus
  • Consensus Cheap
  • Engulfing Bullish
  • HALO 100
  • HALO 50
  • HALO All
  • HALO Consensus Value
  • HALO Earnings Momentum
  • HALO GARP
  • HALO Growth
  • HALO Small

Key Fundamentals

EPS 3 yr Growth

-80.20%

EBITDA Margin

8.40%

Operating Cashflow

$50m

Free Cash Flow Return

13.70%

ROIC

0.80%

Interest Coverage

2.90

Quick Ratio

2.00

Performance

52 weeks range

Low 0.83 - 1.82

Trade Value (12mth)

US$5,418,194.00

1 week

2.23%

1 month

-7.8%

YTD

-30.55%

1 year

-17.8%

All time high

50.02

Additional Data

Shares Outstanding (Fully Diluted)

800m

HALO Sector

Healthcare

Next Company Report Date

18-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

Consensus

Lock Icon

Unlock full consensus

Consensus score

Lock Icon/10

Recommendation

Buy

Target price

Lock Icon

Deviation

Lock Icon

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Weak

Garp

Very Strong

Mqv Small

Neutral

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

Valuation

Lock Icon

Unlock full dataset

Value

Lock Icon

Consensus

Lock Icon

Yield

Lock Icon

News & Announcements

No announcements available.

Key Stakeholders

NameTitle
Mireille SandersIndividual
Anurag RelanIndividual
Ruud van OutersterpIndividual
Alexander BreidenbachIndividual
Mark Jerome PykettIndividual

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial
Want to learn more?Frequently asked questions.
1
What is the current share price of Pharming Group NV (PHARM:AMS)?
Halo FAQ
The current share price of Pharming Group NV (PHARM:AMS) is EUR€0.99.
2
What is the 52-week high share price for Pharming Group NV (PHARM:AMS)?
Halo FAQ
The 52-week high share price for Pharming Group NV (PHARM:AMS) is EUR€1.82.
3
What is the 52-week low share price for Pharming Group NV (PHARM:AMS)?
Halo FAQ
The 52-week low share price for Pharming Group NV (PHARM:AMS) is EUR€0.83.
4
What is the dividend yield for Pharming Group NV (PHARM:AMS)?
Halo FAQ
Pharming Group NV (PHARM:AMS) does not pay a dividend.
5
What was Pharming Group NV (PHARM:AMS) last dividend payment?
Halo FAQ
Pharming Group NV (PHARM:AMS) does not pay a dividend.
6
What is the franking level for Pharming Group NV (PHARM:AMS)?
Halo FAQ
Pharming Group NV (PHARM:AMS) has a franking level of 0.00%.
7
In which sector is Pharming Group NV (PHARM:AMS) classified?
Halo FAQ
Pharming Group NV (PHARM:AMS) is classified in the Healthcare.
8
What is the price-to-earnings (P/E) ratio for Pharming Group NV (PHARM:AMS)?
Halo FAQ
The current P/E ratio for Pharming Group NV (PHARM:AMS) is 385.40.